TITLE

Vildagliptin was effective as add-on therapy in type 2 diabetes inadequately controlled with metformin monotherapy: COMMENTARY

AUTHOR(S)
Basu, Ananda
PUB. DATE
September 2007
SOURCE
ACP Journal Club;Sept/Oct2007, Vol. 147 Issue 2, p47
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The article offers the author's comments on a clinical trial that states that vildagliptin was effective as add-on therapy in type 2 diabetes inadequately controlled with metformin monotherapy. While the author acknowledges the positive results, he cautions that the dipeptidyl peptidase or DPP-IV system (or CD26) has an immunomodulatory role on T-cell activation.
ACCESSION #
27029980

 

Related Articles

  • Vildagliptin was effective as add-on therapy in type 2 diabetes inadequately controlled with metformin monotherapy.  // ACP Journal Club;Sept/Oct2007, Vol. 147 Issue 2, p47 

    The article discusses a clinical trial that states that vildagliptin was effective as add-on therapy in type 2 diabetes inadequately controlled with metformin monotherapy. Details related to the methodology, the randomized placebo-controlled trial-design, patients, and the main results are...

  • Saxagliptin. Dhillon, Sohita; Weber, Juliane // Drugs;2009, Vol. 69 Issue 15, p2103 

    â–´Saxagliptin and its active metabolite M2 are dipeptidyl peptidase-4 inhibitors that improve glycaemic control by preventing the inactivation of the incretin hormones glucagon-like peptide-l (GLP- 1) and glucose-dependent insulinotropic polypeptide. This increases GLP-l levels, stimulates...

  • Investigational DPP-IV inhibitor at various doses reduced HbA1c in type 2 diabetes. Costa, Samantha; Fisher, Stacey L.; Foster, Melissa // Endocrine Today;Nov2012, Vol. 10 Issue 11, p31 

    The article reports on a study which found that an investigational, once-weekly dipeptidyl peptidase-intravenous (DPP-IV) inhibitor significantly lowered HbA1c in type 2 diabetes.

  • Sitagliptin and Vildagliptin: Efficacy of Therapy in Type 2 Diabetes. Kirk, Julienne K.; Oldham, Elizabeth C. // Recent Patents on Endocrine, Metabolic & Immune Drug Discovery;Nov2008, Vol. 2 Issue 3, p162 

    The clinical efficacy and tolerability of dipeptidyl peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes is supported by published clinical trials. Primary literature and review articles were obtained via a Pubmed search (2002-2008) using the search terms diabetes, sitagliptin,...

  • Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures. MONAMI, MATTEO; DICEMBRINI, ILARIA; ANTENORE, ALESSANDRO; MANNUCCI, EDOARDO // Diabetes Care;Nov2011, Vol. 34 Issue 11, p2474 

    OBJECTIVE--Thiazolidinediones and insulin are associated with a higher risk of fractures in type 2 diabetic patients. Incretin hormones increase bone density in experimental models, but the effect of dipeptidyl peptidase-4 (DPP-4) inhibitors on bone fractures has not been reported so far....

  • Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus Patients with Moderate to Severe Renal Impairment: A Systematic Review and Meta-Analysis. Cheng, Dongsheng; Fei, Yang; Liu, Yumei; Li, Junhui; Chen, Yuqiang; Wang, Xiaoxia; Wang, Niansong // PLoS ONE;Oct2014, Vol. 9 Issue 10, p1 

    Objective: To perform a systematic review and meta-analysis regarding the efficacy and safety of dipeptidyl peptidase-4 (DDP-4) inhibitors (“gliptins”) for the treatment of type 2 diabetes mellitus (T2DM) patients with moderate to severe renal impairment. Methods: All available...

  • Erratum.  // Diabetes Care;Jan2014, Vol. 37 Issue 1, following p312 

    A correction to the article "Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures: A Meta-analysis of Randomized Clinical Trials" in the 2014 issue is presented.

  • Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin. Russo, Eleonora; Penno, Giuseppe; Del Prato, Stefano // Diabetes, Metabolic Syndrome & Obesity: Targets & Therapy;Apr2013, Vol. 6, p161 

    Background: Dipeptidyl peptidase-4 (DPP-4) inhibitors are novel classified oral anti-diabetic drugs for the treatment of type 2 diabetes mellitus (T2DM) that provide important reduction in glycated hemoglobin, with a low risk for hypoglycemia and no weight gain. In T2DM patients with reduced...

  • Vildagliptin. Schiesselman, Lauren S. // Formulary;Oct2006, Vol. 41 Issue 10, p494 

    Despite the variety of medications available to treat type 2 diabetes, the disease is inadequately controlled in many patients. In order to improve glycemic control, manufacturers are pursuing compounds that affect the incretin hormones that stimulate insulin release in response to increased...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics